ArticleNeuroepidemiology2026
Temporal Trends in the Incidence and Prevalence of Multiple Sclerosis in Sweden, 2001-2021.
Article in Neuroepidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUnderstanding secular trends in demographic patterns of multiple sclerosis (MS) may help elucidate its etiopathogenesis and is also important for future resource allocation and planning healthcare strategies. Though several incidence and prevalence studies exist, nationwide studies utilizing contemporary data collected over decades remain rare. The objective of this study was to determine changes in incidence and prevalence of MS in Sweden from 2001 to 2021.
methodsLeveraging data from multiple linked population-based registries, we utilized two case definitions: one administrative (based on International Classification of Disease codes from inpatient and outpatient visits, 2006-2021) and one clinical (based on the Swedish MS registry, 2001-2021). We estimated the overall and annual incidence and point prevalence using both definitions and age-standardized to the world standard population. Temporal trends in incidence and prevalence were analyzed using joinpoint and binomial regression, respectively.
resultsIn total, 13,055 incident and 28,107 prevalent MS cases were identified in the administrative data. The overall age-standardized incidence rate was 8.37 (95% confidence interval [CI] 8.22-8.52) cases per 100,000 person-years. Incidence rates were stable until 2012, then decreased until 2021 (annual percent change -2.51%; 95% CI: -5.04% to -1.69%), which translated into a decrease in number of new MS cases from 796 in 2006 to 701 in 2021, or -12.0%. In the clinical data, the overall age-standardized incidence was 7.87 (95% CI: 7.74-7.99) cases per 100,000 person-years. Incidence increased between 2001 and 2014 with an annual percent change of 2.00% (95% CI: 1.40%-2.84%) and thereafter decreased through 2021 with an annual percent change of -2.84% (95% CI: -5.06 to -1.49%). The age-standardized prevalence of MS in the administrative cohort increased from 118 cases per 100,000 (95% CI: 116 to 120) in 2006 to 167 cases per 100,000 (95% CI: 164 to 169) in 2021, i.e., an increase of 41.7%. Similarly, in the clinical cohort, prevalence increased from 71 (95% CI: 69 to 72) to 154 (95% CI: 151 to 156) cases per 100,000 persons from 2001 to 2021, representing an increase of 117.9% Conclusion: Our findings demonstrate a decreasing incidence of MS in the last decade, while prevalence continuously increased. Although confounding by changes in data density cannot be excluded, this may reflect changes in environmental exposures such as smoking, as well as contemporary treatment practices and a secular trend toward milder disease with reduced mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.